In July 2026, an external advisory panel selected by the Department of Health and Human Services recommended that the FDA remove compounding restrictions on six out of seven reviewed peptides, including BPC-157

Overview Debates Related claims Topics Sources

US health policy & drug pricing

Evolving US policy battles over drug pricing and healthcare affordability, tracking legislation, court rulings, regulatory actions, and industry responses shaping costs, access, and market dynamics.

218 claims·78 news stories